PD-L1 on the surface of tumor cells binds its receptor PD-1 on effector T cells, thereby suppressing their activity. Antibody blockade of PD-L1 can activate an anti-tumor immune response leading to durable remissions in a subset of cancer patients. Here, we describe an alternative mechanism o...
19. Shin J, Chung J-H, Kim SH, et al. Effect of platinum-based chemotherapy on PD-L1 expression on tumor cells in non-small cell lung cancer. Cancer Res Treat. 2019;51(3):1086-1097. 20. Rimm DL, Han G, Taube JM, et al. A prospective, multi-institutional, pathologist-based asse...
The interaction between programmed cell death ligand 1 (PD-L1), which is expressed on the surface of tumor cells, and programmed cell death 1 (PD-1), which... R Wang,S He,J Long,... - 《Experimental Hematology & Oncology》 被引量: 0发表: 2024年 The role of radiotherapy in tumor ...
SunLL, YangRY, LiCW, et al.Inhibition of ATR downregulates PD-L1 and sensitizes tumor cells to T cell-mediated killing[J].Am J Cancer Res, 2018, 8(7): 1307-1316. SatoH, NiimiA, YasuharaT, et al.DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells[J]....
To investigate the expression of programmed death-ligand 1 (PD-L1) and immune checkpoints and their prognostic value for resected head and neck squamous cell cancer (HNSCC). PD-L1 expression on tumor cells (TC) and tumor-infiltrating immune cells (IC), abundance of tumor-infiltrating ...
23. Liang H, Deng L, Chmura S, Burnette B, Liadis N, Darga T,et al. Radiation-induced equilibrium is a balance between tumor cell proliferation and T cell-mediated killing. J Immunol 2013;190:5874-81. 24. Shiras...
we describe an alternative mechanism of PD-L1 activity involving its secretion in tumor-derived exosomes. Removal of exosomal PD-L1 inhibits tumor growth, even in models resistant to anti-PD-L1 antibodies. Exosomal PD-L1 from the tumor suppresses T cell activation in the draining lymph node. Sy...
6. Circulating Tumor Cell PD‐L1 Expression as Biomarker for Therapeutic Efficacy of Immune Checkpoint Inhibition in NSCLC. 安龙基因 安龙基因是由安龙生命科学基金携手清华大学医学院共同发起成立的高科技生物医药企业。公司以“一个样本一个生命,一份报告一份希望”为...
As tumor PD-L1 provides signals to anti-tumor PD-1^(+)T cells that blunt their functions,伪PD-1 and伪PD-L1 antibodies have been developed as anti-cancer immunotherapies based on interrupting this signaling axis.However,tumor cell-intrinsic PD-L1 signals also regulate immune-independent tumor ...
双特异性T细胞衔接器(bispecific T-cell engager,BiTE)是一种能够同时结合肿瘤相关抗原(tumor associate antigen,TAA)和 CD3 复合物的抗体类抗肿瘤药物。传统的技术是通过靶向TAA 来实现肿瘤内T细胞上CD3信号通路的再激活,从而达到杀伤肿瘤细胞的效果【1-3】。自上世纪90年代起,针对双特异性抗体疗法的设计和改进已经...